Optimum is delighted to see client, Renee Aguiar-Lucander, CEO of Calliditas Therapeutics interviewed as part of Labiotech’s #WomenInBiotech series.
Many biotech founders and executives look to VC investors for advice and inspiration, but the attraction can go both ways. After more than a decade of investing in life science companies, Renee Aguiar-Lucander, now CEO of Calliditas Therapeutics, decided it was time to try sitting on the other side of the table.
Prior to moving over into biotech, Aguiar-Lucander worked in life science VC investment in London. She was a partner and COO at Omega Fund Management and also worked as a partner at the 3i Group. She also has more than 12 years experience working in investment banking and corporate finance.
This article was written by Helen Albert for Labiotech.eu for more information click here